MCAM Antibody [N21F20] | Primary Antibodies

Application: Reactivity: Human, Mouse

Lane 1: MEF, Lane 2: A375, Lane 3: HUVEC, Lane 4: SK-MEL-28

Usage Information

Dilution
WB1:1000 IP1:50 IHC1:50 - 1:200 IF1:800 - 1:1600 FCM1:100 - 1:400

Application
WB, IP, IHC, IF, FCM

Reactivity
Human, Mouse

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
120 kDa

Positive Control	Mouse liver; Mouse colon; Mouse lung; Normal mouse testis; Mouse lung; Mouse ovary; Human melanoma; Human T-cell lymphoma; Human non-Hodgkin lymphoma; Human mucoepidermoid carcinoma; Human colon carcinoma; Human renal cell carcinoma; SK-MEL-28 cells
Negative Control	Colo 205 cells; LNCaP cells

Datasheet & SDS

Biological Description

Specificity
MCAM Antibody [N21F20] detects endogenous levels of total MCAM protein.

Clone
N21F20

Synonym(s)
Cell surface glycoprotein MUC18; Cell surface glycoprotein P1H12; Melanoma cell adhesion molecule; Melanoma-associated antigen A32; Melanoma-associated antigen MUC18; S-endo 1 endothelial-associated antigen; CD146; MCAM; MUC18

Background
MCAM (Melanoma Cell Adhesion Molecule, CD146/MUC18) is a key immunoglobulin superfamily adhesion protein expressed on vascular endothelium, activated T cells, smooth muscle, pericytes, and mesenchymal stem cells, mediating both homophilic and heterophilic interactions with ligands such as laminin 411, galectin-1, and Netrin-1 to regulate cell migration, angiogenesis, immune surveillance, and hematopoietic niche maintenance. MCAM is a heavily N-glycosylated type I transmembrane glycoprotein consisting of five extracellular Ig-like domains (two N-terminal V-type and three C2-type), a transmembrane helix, and alternatively spliced cytoplasmic tails: the long form contains dileucine and signaling motifs plus PKC phosphorylation sites for endocytosis and basolateral targeting, while the short form has a PDZ-binding domain; additionally, metalloprotease-mediated shedding generates soluble MCAM. Endothelial MCAM is crucial for maintaining vascular junction integrity and promoting angiogenesis, facilitates T lymphocyte transmigration across the blood-brain barrier in multiple sclerosis via IL-17 signaling, supports mesenchymal stromal cell–hematopoietic stem cell contact through Notch signaling, and drives melanoma epithelial-mesenchymal transition. Increased MCAM expression is associated with tumor progression and metastasis in melanoma, prostate, and ovarian cancers, chronic inflammation in rheumatoid arthritis, IBD, and Crohn’s disease, as well as renal dysfunction and diabetic nephropathy, where soluble MCAM serves as a disease biomarker.

Background

MCAM (Melanoma Cell Adhesion Molecule, CD146/MUC18) is a key immunoglobulin superfamily adhesion protein expressed on vascular endothelium, activated T cells, smooth muscle, pericytes, and mesenchymal stem cells, mediating both homophilic and heterophilic interactions with ligands such as laminin 411, galectin-1, and Netrin-1 to regulate cell migration, angiogenesis, immune surveillance, and hematopoietic niche maintenance. MCAM is a heavily N-glycosylated type I transmembrane glycoprotein consisting of five extracellular Ig-like domains (two N-terminal V-type and three C2-type), a transmembrane helix, and alternatively spliced cytoplasmic tails: the long form contains dileucine and signaling motifs plus PKC phosphorylation sites for endocytosis and basolateral targeting, while the short form has a PDZ-binding domain; additionally, metalloprotease-mediated shedding generates soluble MCAM. Endothelial MCAM is crucial for maintaining vascular junction integrity and promoting angiogenesis, facilitates T lymphocyte transmigration across the blood-brain barrier in multiple sclerosis via IL-17 signaling, supports mesenchymal stromal cell–hematopoietic stem cell contact through Notch signaling, and drives melanoma epithelial-mesenchymal transition. Increased MCAM expression is associated with tumor progression and metastasis in melanoma, prostate, and ovarian cancers, chronic inflammation in rheumatoid arthritis, IBD, and Crohn’s disease, as well as renal dysfunction and diabetic nephropathy, where soluble MCAM serves as a disease biomarker.

References
https://pubmed.ncbi.nlm.nih.gov/34830300/ https://pubmed.ncbi.nlm.nih.gov/33352759/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%